Adverum Biotechnologies PE Ratio 2013-2021 | ADVM

Current and historical p/e ratio for Adverum Biotechnologies (ADVM) from 2013 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Adverum Biotechnologies PE ratio as of October 22, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Adverum Biotechnologies PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-22 1.95 0.00
2021-06-30 3.50 $-1.44 0.00
2021-03-31 9.86 $-1.35 0.00
2020-12-31 10.84 $-1.37 0.00
2020-09-30 10.30 $-1.27 0.00
2020-06-30 20.88 $-1.21 0.00
2020-03-31 9.77 $-1.08 0.00
2019-12-31 11.52 $-1.00 0.00
2019-09-30 5.45 $-0.96 0.00
2019-06-30 11.89 $-1.05 0.00
2019-03-31 5.24 $-1.12 0.00
2018-12-31 3.15 $-1.19 0.00
2018-09-30 6.05 $-1.26 0.00
2018-06-30 5.30 $-1.24 0.00
2018-03-31 5.80 $-1.21 0.00
2017-12-31 3.50 $-1.29 0.00
2017-09-30 3.65 $-1.51 0.00
2017-06-30 2.50 $-1.54 0.00
2017-03-31 2.70 $-3.03 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.191B $0.000B
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum?s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76